Literature DB >> 17574099

STAT1 and STAT3 as intracellular regulators of vascular remodeling.

Andrzej Wincewicz1, Mariola Sulkowska, Ryszard Rutkowski, Stanislaw Sulkowski, Boguslaw Musiatowicz, Tomasz Hirnle, Waldemar Famulski, Mariusz Koda, Grzegorz Sokol, Przemyslaw Szarejko.   

Abstract

The roles of signal transducers and activators of transcription (STAT) proteins are widely discussed in the pathogenesis of cardiovascular diseases. It is highly probable that STAT1 and STAT3 are activated during proliferation and inflammation inside atheromatous plaques. Luminal surfaces of endothelium become thrombogenic because of STAT1-dependent induction of MHC II and STAT3-regulated recruitment of phospholipase A2. As with STAT1, STAT3 seems to mediate stimulation of vascular wall cells by VEGF, HGF, and Ang II. STAT3 can contribute to counteracting apoptosis by eventual cooperation with c-fos and the bcl-xl gene. As pharmacological agents called statins are reported to regulate activities of STAT proteins, these signal messenger proteins could serve as targets for anti-atherogenic therapy. We attempted to review the role of STAT1 and STAT3 proteins in vascular remodeling.

Entities:  

Year:  2007        PMID: 17574099     DOI: 10.1016/j.ejim.2006.12.007

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  13 in total

1.  Down-Regulation of ID2-AS1 Alleviates the Neuronal Injury Induced by 1-Methy1-4-Phenylpyridinium in Human Neuroblastoma Cell Line SH-SY5Y Cells Through Regulating miR-199a-5p/IFNAR1/JAK2/STAT1 Axis.

Authors:  Furong Xu; Hui Wang; Ju Tian; Haiyan Xu
Journal:  Neurochem Res       Date:  2021-05-29       Impact factor: 3.996

2.  ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio.

Authors:  Nuala J Meyer; Mingyao Li; Rui Feng; Jonathan Bradfield; Robert Gallop; Scarlett Bellamy; Barry D Fuchs; Paul N Lanken; Steven M Albelda; Melanie Rushefski; Richard Aplenc; Helen Abramova; Elena N Atochina-Vasserman; Michael F Beers; Carolyn S Calfee; Mitchell J Cohen; Jean-Francois Pittet; David C Christiani; Grant E O'Keefe; Lorraine B Ware; Addison K May; Mark M Wurfel; Hakon Hakonarson; Jason D Christie
Journal:  Am J Respir Crit Care Med       Date:  2011-01-21       Impact factor: 21.405

Review 3.  The hyper-IgE syndromes.

Authors:  Alexandra F Freeman; Steven M Holland
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

Review 4.  Roles of STATs signaling in cardiovascular diseases.

Authors:  Raj Kishore; Suresh K Verma
Journal:  JAKSTAT       Date:  2012-04-01

Review 5.  Emerging translational approaches to target STAT3 signalling and its impact on vascular disease.

Authors:  Jochen Dutzmann; Jan-Marcus Daniel; Johann Bauersachs; Denise Hilfiker-Kleiner; Daniel G Sedding
Journal:  Cardiovasc Res       Date:  2015-03-17       Impact factor: 10.787

Review 6.  Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease.

Authors:  Malgorzata Szelag; Anna Piaszyk-Borychowska; Martyna Plens-Galaska; Joanna Wesoly; Hans A R Bluyssen
Journal:  Oncotarget       Date:  2016-07-26

7.  SOCS1 gene promoter methylation status is associated with in-stent restenosis after percutaneous coronary intervention.

Authors:  Liang Zhou; Ningfu Wang; Hong Li; Guoxin Tong; Jianmin Yang; Lei Lai; Hao Pan; Xianhua Ye; Jinyu Huang
Journal:  Oncotarget       Date:  2017-06-07

8.  Stat1 nuclear translocation by nucleolin upon monocyte differentiation.

Authors:  Uwe Jerke; Sergey Tkachuk; Julia Kiyan; Victoria Stepanova; Angelika Kusch; Michael Hinz; Rainer Dietz; Hermann Haller; Bianca Fuhrman; Inna Dumler
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

9.  Pravastatin prevents aortic atherosclerosis via modulation of signal transduction and activation of transcription 3 (STAT3) to attenuate interleukin-6 (IL-6) action in ApoE knockout mice.

Authors:  Xiaoxu Zhou; Dan Li; Wei Yan; Weimin Li
Journal:  Int J Mol Sci       Date:  2008-11-14       Impact factor: 6.208

10.  Genome-Wide Inhibition of Pro-atherogenic Gene Expression by Multi-STAT Targeting Compounds as a Novel Treatment Strategy of CVDs.

Authors:  Martyna Plens-Galaska; Malgorzata Szelag; Aida Collado; Patrice Marques; Susana Vallejo; Mariella Ramos-González; Joanna Wesoly; María Jesus Sanz; Concepción Peiró; Hans A R Bluyssen
Journal:  Front Immunol       Date:  2018-09-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.